Research advancements of antibody drug conjugates in non-small cell lung cancer with HER2 alterations

Research advancements of antibody drug conjugates in non-small cell lung cancer with HER2 alterations

Abstract The human epidermal growth factor receptor 2 (HER2) alterations are significant genetic alterations in non-small cell lung cancer (NSCLC), encompassing mutations, amplifications, and protein overexpression. Despite the substantial progress of anti-HER2 targeted therapies in breast and gastr...

Full description

Saved in:
Bibliographic Details
Main Authors: Jiang Liu, Jianhua Liu, Jianhe Yu, Qun Ren, Yin Cai, Dadong Chen, Chuanjun Song
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Journal of Translational Medicine
Subjects:
Human epidermal growth factor receptor 2
HER2
Non-small cell lung cancer
Antibody drug conjugates
T-DM1
T-DXd
Online Access:https://doi.org/10.1186/s12967-025-06589-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12967-025-06589-x

Similar Items